WO2007056113A9 - Methods for targeting quadruplex sequences - Google Patents

Methods for targeting quadruplex sequences Download PDF

Info

Publication number
WO2007056113A9
WO2007056113A9 PCT/US2006/042906 US2006042906W WO2007056113A9 WO 2007056113 A9 WO2007056113 A9 WO 2007056113A9 US 2006042906 W US2006042906 W US 2006042906W WO 2007056113 A9 WO2007056113 A9 WO 2007056113A9
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
methods
quadruplex sequences
quadruplex
sequences
Prior art date
Application number
PCT/US2006/042906
Other languages
French (fr)
Other versions
WO2007056113A2 (en
Inventor
Sean O'brien
Adam Siddiqui-Jain
Original Assignee
Cylene Pharmaceuticals Inc
Sean O'brien
Adam Siddiqui-Jain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cylene Pharmaceuticals Inc, Sean O'brien, Adam Siddiqui-Jain filed Critical Cylene Pharmaceuticals Inc
Priority to US12/092,557 priority Critical patent/US20090291437A1/en
Publication of WO2007056113A2 publication Critical patent/WO2007056113A2/en
Publication of WO2007056113A9 publication Critical patent/WO2007056113A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
PCT/US2006/042906 2005-11-02 2006-11-02 Methods for targeting quadruplex sequences WO2007056113A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/092,557 US20090291437A1 (en) 2005-11-02 2006-11-02 Methods for targeting quadruplex sequences

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73253105P 2005-11-02 2005-11-02
US60/732,531 2005-11-02
US73568605P 2005-11-10 2005-11-10
US60/735,686 2005-11-10

Publications (2)

Publication Number Publication Date
WO2007056113A2 WO2007056113A2 (en) 2007-05-18
WO2007056113A9 true WO2007056113A9 (en) 2009-03-05

Family

ID=38023820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042906 WO2007056113A2 (en) 2005-11-02 2006-11-02 Methods for targeting quadruplex sequences

Country Status (2)

Country Link
US (1) US20090291437A1 (en)
WO (1) WO2007056113A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3092901B1 (en) * 2007-10-05 2020-04-29 Senhwa Biosciences, Inc. Quinolone analogs and methods related thereto
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
CA2888486A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
SG11201602597YA (en) 2013-10-11 2016-05-30 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015057727A1 (en) * 2013-10-14 2015-04-23 Isis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
AU2014337506B2 (en) * 2013-10-14 2020-10-15 Ionis Pharmaceuticals, Inc. Methods for modulating expression of C9ORF72 antisense transcript
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US11260073B2 (en) 2015-11-02 2022-03-01 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating C90RF72
US10857156B2 (en) 2015-11-20 2020-12-08 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
JOP20190045A1 (en) 2016-09-14 2019-03-14 Bayer Ag 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
CN111278991B (en) 2017-08-25 2022-04-01 斯托克制药公司 Antisense oligomers for the treatment of conditions and diseases
CA3088998A1 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
EP3768694A4 (en) * 2018-03-22 2021-12-29 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
US20210333284A1 (en) * 2020-04-28 2021-10-28 Purdue Research Foundation Methods and materials for large-scale assessment of ligand binding selectivity of g-quadruplex recognition using custom g4 microarrays

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) * 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4469863A (en) * 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) * 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
US4868103A (en) * 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5321131A (en) * 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
EP0552108B1 (en) * 1992-01-17 1999-11-10 Lakowicz, Joseph R. Energy transfer phase-modulation fluoro-immunoassay
SE9201984D0 (en) * 1992-06-29 1992-06-29 Pharmacia Biosensor Ab IMPROVEMENT IN OPTICAL ASSAYS
RU95104940A (en) * 1992-07-27 1997-01-10 Хайбрайдон Method of incorporation of alkylphosphonothioate or arylphosphonothioate internucleotide linkage in oligonucleotide, method of oligonucleotide synthesis, method of gene expression inhibition, treatment method
EP0680489A1 (en) * 1993-01-21 1995-11-08 HYBRIDON, Inc. Foldback triplex-forming oligonucleotides
US5637684A (en) * 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
WO1995023865A1 (en) * 1994-03-03 1995-09-08 Genentech, Inc. Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
AU701342B2 (en) * 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5614622A (en) * 1995-06-01 1997-03-25 Hybridon, Inc. 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses
US5962674A (en) * 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
US6140482A (en) * 1995-06-01 2000-10-31 Hybridon, Inc. Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same
US5955599A (en) * 1995-06-01 1999-09-21 Hybridon, Inc. Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
US5637683A (en) * 1995-07-13 1997-06-10 Cornell Research Foundation, Inc. Nucleic acid analog with amide linkage and method of making that analog
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
SE9503028D0 (en) * 1995-09-01 1995-09-01 Pharmacia Biosensor Ab Method of analyzing chemical and physical interactions on a sensor surface
GB9518429D0 (en) * 1995-09-08 1995-11-08 Pharmacia Biosensor A rapid method for providing kinetic and structural data in molecular interaction analysis
SE9504046D0 (en) * 1995-11-14 1995-11-14 Pharmacia Ab Method of determining affinity and kinetic properties
SE9601318D0 (en) * 1996-04-04 1996-04-04 Pharmacia Biosensor Ab Method for nucleic acid analysis
CA2253710A1 (en) * 1996-04-25 1997-10-30 Spectrametrix Inc. Analyte assay using particulate labels
US6022688A (en) * 1996-05-13 2000-02-08 Sequenom, Inc. Method for dissociating biotin complexes
US5766905A (en) * 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
NZ333346A (en) * 1996-06-28 2000-03-27 Caliper Techn Corp High-throughput screening assay systems in microscale fluidic devices
AU4089397A (en) * 1996-08-26 1998-03-19 Hybridon, Inc. Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US5900481A (en) * 1996-11-06 1999-05-04 Sequenom, Inc. Bead linkers for immobilizing nucleic acids to solid supports
US6133436A (en) * 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
US6447727B1 (en) * 1996-11-19 2002-09-10 Caliper Technologies Corp. Microfluidic systems
US6090919A (en) * 1997-01-31 2000-07-18 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US6235471B1 (en) * 1997-04-04 2001-05-22 Caliper Technologies Corp. Closed-loop biochemical analyzers
US5739314A (en) * 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
US6221612B1 (en) * 1997-08-01 2001-04-24 Aurora Biosciences Corporation Photon reducing agents for use in fluorescence assays
US6100541A (en) * 1998-02-24 2000-08-08 Caliper Technologies Corporation Microfluidic devices and systems incorporating integrated optical elements
US6455263B2 (en) * 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
US6461813B2 (en) * 1998-09-21 2002-10-08 Rigel Pharmaceuticals, Inc. Multiparameter FACS assays to detect alterations in cell cycle regulation
WO2000064946A2 (en) * 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
US6451602B1 (en) * 2000-03-02 2002-09-17 Isis Pharmaceuticals, Inc. Antisense modulation of PARP expression
US6451538B1 (en) * 2000-12-22 2002-09-17 Isis Pharmaceuticals, Inc. Antisense modulation of CHK2 expression
US6455307B1 (en) * 2001-02-08 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of casein kinase 2-alpha prime expression
US6455308B1 (en) * 2001-08-01 2002-09-24 Isis Pharmaceuticals, Inc. Antisense modulation of serum amyloid A4 expression
ATE508188T1 (en) * 2002-02-01 2011-05-15 Life Technologies Corp OLIGONUCLEOTIDE COMPOSITIONS WITH IMPROVED EFFECTIVENESS
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20040005601A1 (en) * 2002-04-05 2004-01-08 Adam Siddiqui-Jain Methods for targeting quadruplex DNA
AU2003272389A1 (en) * 2002-09-12 2004-04-30 Cyternex, Inc. Expanded porphyrin compositions for tumor inhibition

Also Published As

Publication number Publication date
US20090291437A1 (en) 2009-11-26
WO2007056113A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2007056113A9 (en) Methods for targeting quadruplex sequences
EP1881847B8 (en) Injection solution for rna
WO2006116444A8 (en) Tissue-treatment methods
EP1756738A4 (en) Content-management system for user behavior targeting
AU2007282582A1 (en) Refrigeration apparatus
AU2007332157A8 (en) Flux chamber
EP1860064B8 (en) Fuel modification apparatus
AU2005907111A0 (en) Backyard cricket
AU2006903509A0 (en) Improved method
AU2006903591A0 (en) A-board
AU2006100279A4 (en) Backyard football
AU2006906425A0 (en) Chromatography method
AU2006902374A0 (en) Novel therapeutic method
AU2006903765A0 (en) Backyard 20/20 cricket kit
AU2005903247A0 (en) Cashew harvesting apparatus
AU2006900509A0 (en) Method
AU2005905025A0 (en) Method
AU2005901882A0 (en) Improved connector
AU2006900295A0 (en) Improved Gyro-Stabiliser
AU2006901097A0 (en) Improved leadlight
AU2005903324A0 (en) Targeting vector
AU2006903508A0 (en) Improved Process
AU2005900380A0 (en) Keg connector
AU2006902169A0 (en) Improved hitch assembly
AU2005902754A0 (en) Magnetic Tube Connector

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12092557

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 06844254

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)